| Stereochemistry | RACEMIC |
| Molecular Formula | C22H24ClN3OS.2ClH |
| Molecular Weight | 486.885 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.ClC1=CC=C2SC3=C(C=CC=C3)N(C(=O)CCN4CCN5CCCC5C4)C2=C1
InChI
InChIKey=UERHIZBSLAGDLU-UHFFFAOYSA-N
InChI=1S/C22H24ClN3OS.2ClH/c23-16-7-8-21-19(14-16)26(18-5-1-2-6-20(18)28-21)22(27)9-11-24-12-13-25-10-3-4-17(25)15-24;;/h1-2,5-8,14,17H,3-4,9-13,15H2;2*1H
Nonachlazine is an original drug synthesized in the Institute of Pharmacology, Academy of Medical Sciences of the USSR. The results of clinical trials have shown that Nonachlazine is an antianginal agent distinguished by its high efficacy in the treatment of ischemic heart disease. Experimental studies have shown that an important role in the mechanism of the antianginal effect of nonachlazine is played by its effect on adrenergic processes of regulation of the circulation and cardiac activity. Nonachlazine increases the noradrenalin concentration and activity of phosphorylase "a" in the myocardium. These findings suggest that the beneficial effect of nonachlazine is evidently associated with its ability to activate adrenergic mechanisms in the regulation of glycogenolysis. Yonahlazin is used in patients who do not tolerate nitroglycerin or who have contraindications to its use. Nonahlazin in solution, unlike nitroglycerin, does not lower arterial pressure and does not cause dizziness, but often nitroglycerin more effectively eliminates an attack than Nonachlazine.
Approval Year
PubMed
Patents
Sample Use Guides
Chronic ischemic heart disease: 0,03 g (1 tablet) for 1 hour before meals 3-4 times a day for 3-4 weeks.
Preinfarction angina: 5ml of 1,5% solution 3 times per day for 3 days. After that 1 tablet 4-8 times per day for 3-4 weeks.
Angina pectoris: 5-10 ml of 1,5% solution. Repeat after 4-5 hours. Do not exceed daily dose - 30 ml.
Route of Administration:
Oral
Experiments on the ischemic myocardial tissue of the rat in vitro showed that despite the fact that reserpine-induced depletion of the tissue catecholamine storage failed to affect the stability of lysosomal membranes, a combination of reserpine pretreatment of the animals with subsequent administration of nonachlazine at the low dose yielded stabilization of lysosomal membranes to a greater extent than administration of nonachlazine alone. The effects of nonachlazine (0.25 mg/kg) on the activity of creatine phosphokinase and total activity of acid phosphatase with and without reserpine pretreatment were similar.
ACTIVE MOIETY
SUBSTANCE RECORD
